Circulating metabolic signatures of rapid and slow progression to type 1 diabetes in islet autoantibody-positive children
- PMID: 37745723
- PMCID: PMC10516565
- DOI: 10.3389/fendo.2023.1211015
Circulating metabolic signatures of rapid and slow progression to type 1 diabetes in islet autoantibody-positive children
Abstract
Aims/hypothesis: Appearance of multiple islet cell autoantibodies in early life is indicative of future progression to overt type 1 diabetes, however, at varying rates. Here, we aimed to study whether distinct metabolic patterns could be identified in rapid progressors (RP, disease manifestation within 18 months after the initial seroconversion to autoantibody positivity) vs. slow progressors (SP, disease manifestation at 60 months or later from the appearance of the first autoantibody).
Methods: Longitudinal samples were collected from RP (n=25) and SP (n=41) groups at the ages of 3, 6, 12, 18, 24, or ≥ 36 months. We performed a comprehensive metabolomics study, analyzing both polar metabolites and lipids. The sample series included a total of 239 samples for lipidomics and 213 for polar metabolites.
Results: We observed that metabolites mediated by gut microbiome, such as those involved in tryptophan metabolism, were the main discriminators between RP and SP. The study identified specific circulating molecules and pathways, including amino acid (threonine), sugar derivatives (hexose), and quinic acid that may define rapid vs. slow progression to type 1 diabetes. However, the circulating lipidome did not appear to play a major role in differentiating between RP and SP.
Conclusion/interpretation: Our study suggests that a distinct metabolic profile is linked with the type 1 diabetes progression. The identification of specific metabolites and pathways that differentiate RP from SP may have implications for early intervention strategies to delay the development of type 1 diabetes.
Keywords: birth cohort; gut microbial metabolites; lipidomics; metabolomics; type 1 diabetes mellitus.
Copyright © 2023 Lamichhane, Sen, Dickens, Kråkström, Ilonen, Lempainen, Hyöty, Lahesmaa, Veijola, Toppari, Hyötyläinen, Knip and Orešič.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Circulating metabolites in progression to islet autoimmunity and type 1 diabetes.Diabetologia. 2019 Dec;62(12):2287-2297. doi: 10.1007/s00125-019-04980-0. Epub 2019 Aug 23. Diabetologia. 2019. PMID: 31444528 Free PMC article.
-
Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility.Diabetologia. 2017 Jul;60(7):1284-1293. doi: 10.1007/s00125-017-4258-7. Epub 2017 Mar 31. Diabetologia. 2017. PMID: 28364254
-
Age- and islet autoimmunity-associated differences in amino acid and lipid metabolites in children at risk for type 1 diabetes.Diabetes. 2011 Nov;60(11):2740-7. doi: 10.2337/db10-1652. Diabetes. 2011. PMID: 22025777 Free PMC article.
-
Metabolomics and Lipidomics Studies in Pediatric Type 1 Diabetes: Biomarker Discovery for the Early Diagnosis and Prognosis.Pediatr Diabetes. 2023 Jul 13;2023:6003102. doi: 10.1155/2023/6003102. eCollection 2023. Pediatr Diabetes. 2023. PMID: 40303249 Free PMC article. Review.
-
What Have Slow Progressors Taught Us About T1D-Mind the Gap!Curr Diab Rep. 2019 Sep 10;19(10):99. doi: 10.1007/s11892-019-1219-1. Curr Diab Rep. 2019. PMID: 31501992 Free PMC article. Review.
Cited by
-
CXADR polymorphism rs6517774 modifies islet autoimmunity characteristics and exhibits sex disparity.Front Genet. 2023 Nov 2;14:1248701. doi: 10.3389/fgene.2023.1248701. eCollection 2023. Front Genet. 2023. PMID: 38028613 Free PMC article.
-
From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes.Metabolites. 2025 Feb 19;15(2):138. doi: 10.3390/metabo15020138. Metabolites. 2025. PMID: 39997763 Free PMC article. Review.
-
SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome.Nat Commun. 2025 Mar 25;16(1):2893. doi: 10.1038/s41467-025-58319-y. Nat Commun. 2025. PMID: 40133336 Free PMC article.
-
Type 1 diabetes: immune pathology and novel therapeutic approaches.Diabetol Int. 2024 Sep 11;15(4):761-776. doi: 10.1007/s13340-024-00748-z. eCollection 2024 Oct. Diabetol Int. 2024. PMID: 39469552 Review.
-
A bibliometric study of global trends in T1DM and intestinal flora research.Front Microbiol. 2024 Jul 4;15:1403514. doi: 10.3389/fmicb.2024.1403514. eCollection 2024. Front Microbiol. 2024. PMID: 39027096 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical